CardioGenesis, Eclipse TMR, PMR Data Updates To Be Presented At ACC
This article was originally published in The Gray Sheet
Executive Summary
Six-month data on 221 patients enrolled in CardioGenesis' U.S. trial of the Axcis percutaneous transmyocardial revascularization (PMR) system show negligible morbidity and a positive safety profile for treatment of no option Class III or IV angina patients.
You may also be interested in...
Laser Myocardial Therapies Under The Beam In Light Of J&J DIRECT Results
Results of a Johnson & Johnson-sponsored trial showing that direct myocardial revascularization (DMR) technology has a placebo-comparable effect should prompt FDA to take a closer look at laser therapies for advanced heart disease patients, trial investigators suggest.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.